Decheng Capital Global Life Sciences Fund IV, L.P. - Jan 29, 2024 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Role: 10%+ Owner
Signature: Decheng Capital Global Life Sciences Fund IV, L.P., By Decheng Capital Management IV (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
Stock symbol: CGON
Transactions as of: Jan 29, 2024
Transactions value $: $7,600,000
Form type: 4
Date filed: 1/31/2024, 04:17 PM
Previous filing: Jan 24, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CGON	Common Stock	Conversion of derivative security		+3.63M	+389.87%		4.56M	Jan 29, 2024	Direct	F1, F2
transaction	CGON	Common Stock	Purchase	$7.6M	+400K		$19.00^*	400K	Jan 29, 2024	By Decheng Capital Global Healthcare Fund (Master), LP	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CGON	Series C Preferred Stock	Conversion of derivative security		-8.64M	-100%		0	Jan 29, 2024	Common Stock	907K		Direct	F1, F2
transaction	CGON	Series E Preferred Stock	Conversion of derivative security		-21.5M	-100%		0	Jan 29, 2024	Common Stock	2.26M		Direct	F1, F2
transaction	CGON	Series F Preferred Stock	Conversion of derivative security		-4.4M	-100%		0	Jan 29, 2024	Common Stock	462K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Decheng Capital Global Life Sciences Fund IV, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
F2	These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F3	These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.